Trade Report: The JPMorgan Chase & Co. Reiterates “Overweight” Rating for Shire PLC (SHPG)

The JPMorgan Chase & Co. Reiterates “Overweight” Rating for Shire PLC (SHPG)

Shire PLC (NASDAQ:SHPG)‘s stock had its “overweight” rating restated by equities researchers at JPMorgan Chase & Co. in a research note issued to investors on Monday.

SHPG has been the subject of several other reports. Zacks Investment Research upgraded shares of Shire PLC from a “sell” rating to a “hold” rating in a research note on Thursday, August 4th. Citigroup Inc. reiterated a “buy” rating on shares of Shire PLC in a research note on Tuesday, September 27th. Jefferies Group reiterated a “buy” rating and set a $262.00 price objective on shares of Shire PLC in a research note on Wednesday, September 7th. BTIG Research reiterated a “buy” rating and set a $230.00 price objective on shares of Shire PLC in a research note on Tuesday, July 12th. Finally, Leerink Swann reiterated a “buy” rating and set a $213.00 price objective on shares of Shire PLC in a research note on Tuesday, July 12th. Five equities research analysts have rated the stock with a hold rating and twenty-two have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $228.15.

Shire PLC (NASDAQ:SHPG) traded down 1.02% during midday trading on Monday, hitting $185.79. The stock had a trading volume of 928,814 shares. The firm has a 50-day moving average of $194.68 and a 200 day moving average of $187.77. Shire PLC has a 52-week low of $147.60 and a 52-week high of $231.32. The firm has a market capitalization of $55.34 billion, a P/E ratio of 38.61 and a beta of 1.16.

Shire PLC (NASDAQ:SHPG) last announced its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.03 by $0.35. The company earned $2.43 million during the quarter, compared to the consensus estimate of $2.28 billion. Shire PLC had a net margin of 13.19% and a return on equity of 17.70%. Shire PLC’s revenue was up 55.9% compared to the same quarter last year. During the same period last year, the firm earned $2.63 earnings per share. On average, equities analysts forecast that Shire PLC will post $12.92 EPS for the current year.

The firm also recently announced a dividend, which was paid on Friday, October 7th. Investors of record on Friday, September 9th were paid a dividend of $0.139 per share. The ex-dividend date of this dividend was Wednesday, September 7th. Shire PLC’s payout ratio is currently 15.63%.

A number of large investors have recently made changes to their positions in the company. Canal Insurance CO acquired a new stake in shares of Shire PLC during the second quarter valued at $102,000. FTB Advisors Inc. increased its stake in shares of Shire PLC by 3.1% in the second quarter. FTB Advisors Inc. now owns 600 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 18 shares during the last quarter. Duncker Streett & Co. Inc. acquired a new stake in shares of Shire PLC during the second quarter valued at $111,000. Quadrant Capital Group LLC increased its stake in shares of Shire PLC by 157.6% in the second quarter. Quadrant Capital Group LLC now owns 608 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 372 shares during the last quarter. Finally, Ropes Wealth Advisors LLC acquired a new stake in shares of Shire PLC during the second quarter valued at $114,000. 24.30% of the stock is currently owned by hedge funds and other institutional investors.

Shire PLC Company Profile

Related posts

Leave a Comment